Riluzole elevates GLT-1 activity and levels in striatal astrocytes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Drugs which upregulate astrocyte glutamate transport may be useful neuroprotective compounds by preventing excitotoxicity. We set up a new system to identify potential neuroprotective drugs which act through GLT-1. Primary mouse striatal astrocytes grown in the presence of the growth-factor supplement G5 express high levels of the functional glutamate transporter, GLT-1 (also known as EAAT2) as assessed by Western blotting and 3H-glutamate uptake assay, and levels decline following growth factor withdrawal. The GLT-1 transcriptional enhancer dexamethasone (0.1 or 1 μM) was able to prevent loss of GLT-1 levels and activity following growth factor withdrawal. In contrast, ceftriaxone, a compound previously reported to enhance GLT-1 expression, failed to regulate GLT-1 in this system. The neuroprotective compound riluzole (100 μM) upregulated GLT-1 levels and activity, through a mechanism that was not dependent on blockade of voltage-sensitive ion channels, since zonasimide (1 mM) did not regulate GLT-1. Finally, CDP-choline (10 μM – 1 mM), a compound which promotes association of GLT-1/EAAT2 with lipid rafts was unable to prevent GLT-1 loss under these conditions. This observation extends the known pharmacological actions of riluzole, and suggests that this compound may exert its neuroprotective effects through an astrocyte-dependent mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 5×
“…transporter function or attenuate neurodegeneration in other cellular systems or in vivo, namely ceftriaxone (Lee et al., 2008; Miller et al., 2008; Rothstein et al., 2005), riluzole (Azbill et al., 2000; Dunlop et al., 2003; Frizzo et al., 2004; Fumagalli et al., 2008), dexamethasone (Zschocke et…”
InfluentialBellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., Kennedy, R. T., & Rebec, G. V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.004 · Cited by 280 · cited 2×
“…astrocyte glutamate transporter function or attenuate neurodegeneration in other cellular systems or in vivo, namely ceftriaxone (Lee et al., 2008; Miller et al., 2008; Rothstein et al., 2005), riluzole (Azbill et al., 2000; Dunlop et al., 2003; Frizzo et al., 2004; Fumagalli et al., 2008),…”
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145
Cited by
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Pajarillo, E., Rizor, A., Lee, J., Aschner, M., & Lee, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.002 · Cited by 478
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection
Kong, Q., Chang, L.-C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., Ibabao, B., Lin, Y., Stouffer, N., Mukhopadhyay, C. D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66163 · Cited by 156
Green, J. L., dos Santos, W. F., & Fontana, A. C. K. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114786 · Cited by 150
Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Sharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Glutamate transport: a new bench to bedside mechanism for treating drug abuse
Spencer, S., & Kalivas, P. W. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx050 · Cited by 71
“, 2011) and augments GLT-1 protein levels and function (Carbone et al., 2012).”
BackgroundChen, J.-X., Yao, L.-H., Xu, B.-B., Qian, K., Wang, H.-L., Liu, Z.-C., Wang, X.-P., & Wang, G.-H. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1362-5 · Cited by 39
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants
Verkhratsky, A., Parpura, V., Scuderi, C., & Li, B. (2021) · Advances in Neurobiology · doi:10.1007/978-3-030-77375-5_13 · Cited by 19
Metadata
- Authors
- Carbone, M., Duty, S., & Rattray, M.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 60
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W1995963726
- Cited by
- 114
- References
- 5
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.